EdgeMarket › What Perceptive Advisors Llc reported owning
What Perceptive Advisors Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
5.1BPositions
94Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 656.0M | 12.8% | 2.0M | 375.94 | +730.8% |
| CELC Celcuity Inc. | 356.9M | 7.0% | 3.1M | 93.53 | +91.8% |
| ASND Ascendis Pharma A/S | 350.3M | 6.8% | 1.5M | 253.29 | +31.4% |
| ROIV Roivant Sciences Ltd. | 229.5M | 4.5% | 8.3M | 36.30 | +209.7% |
| unmapped CUSIP 152309100 | 208.9M | 4.1% | 5.3M | — | — |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 206.4M | 4.0% | 2.4M | 110.00 | +11.4% |
| SYRE Spyre Therapeutics, Inc. | 190.8M | 3.7% | 3.8M | 106.49 | +551.3% |
| unmapped CUSIP 670703107 | 161.9M | 3.2% | 1.6M | — | — |
| EWTX Edgewise Therapeutics, Inc. | 139.4M | 2.7% | 4.4M | 44.18 | +219.2% |
| PTGX Protagonist Therapeutics, Inc | 129.7M | 2.5% | 1.2M | 154.32 | +174.4% |
| APGE Apogee Therapeutics, Inc. | 129.7M | 2.5% | 1.5M | 134.75 | +274.1% |
| TVTX Travere Therapeutics, Inc. | 123.1M | 2.4% | 4.1M | 65.71 | +265.7% |
| AMLX Amylyx Pharmaceuticals, Inc. | 115.2M | 2.3% | 8.3M | 38.66 | +381.4% |
| IMTX Immatics N.V. | 102.2M | 2.0% | 10.4M | 8.93 | +59.5% |
| RLAY Relay Therapeutics, Inc. | 97.0M | 1.9% | 9.8M | 19.44 | +471.8% |
| INBX Inhibrx Biosciences, Inc. | 97.0M | 1.9% | 1.4M | 103.63 | +324.5% |
| MGTX MeiraGTx Holdings plc | 89.3M | 1.7% | 10.3M | 14.34 | +89.7% |
| ZYME Zymeworks Inc. | 87.9M | 1.7% | 3.5M | 28.67 | +100.2% |
| SLDB Solid Biosciences Inc. | 85.7M | 1.7% | 11.9M | 9.30 | +64.3% |
| DYN Dyne Therapeutics, Inc. | 84.6M | 1.7% | 4.7M | 26.10 | +118.0% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 70.8M | 1.4% | 7.4M | 9.55 | +14.0% |
| ORKA Oruka Therapeutics, Inc. | 68.4M | 1.3% | 1.4M | 107.96 | +649.7% |
| AORT ARTIVION, INC. | 60.0M | 1.2% | 1.6M | 28.08 | -34.7% |
| NRIX Nurix Therapeutics, Inc. | 57.5M | 1.1% | 3.7M | 26.72 | +180.4% |
| NAUT Nautilus Biotechnology, Inc. | 48.9M | 1.0% | 12.6M | 0.95 | +38.4% |
| CTMX CytomX Therapeutics, Inc. | 47.5M | 0.9% | 10.1M | 3.28 | +66.5% |
| ANRO Alto Neuroscience, Inc. | 45.2M | 0.9% | 2.0M | 34.28 | +899.4% |
| ENGN enGene Therapeutics Inc. | 39.7M | 0.8% | 5.8M | 1.78 | -53.9% |
| IMVT Immunovant, Inc. | 39.7M | 0.8% | 1.6M | 44.37 | +199.4% |
| ISRG INTUITIVE SURGICAL INC | 39.4M | 0.8% | 85.4K | 378.81 | -21.2% |
| IONS IONIS PHARMACEUTICALS INC | 37.8M | 0.7% | 504.0K | 59.74 | +39.5% |
| unmapped CUSIP 23954D109 | 37.6M | 0.7% | 1.8M | — | — |
| ABVX Abivax S.A. | 36.6M | 0.7% | 328.9K | 114.95 | +59.9% |
| CRVS Corvus Pharmaceuticals, Inc. | 33.5M | 0.7% | 2.3M | 14.46 | +178.6% |
| RGEN REPLIGEN CORP | 33.1M | 0.6% | 280.5K | 181.13 | +49.0% |
| JAZZ Jazz Pharmaceuticals plc | 32.1M | 0.6% | 170.0K | 254.28 | +113.6% |
| DMRA Damora Therapeutics, Inc. | 31.7M | 0.6% | 1.2M | 30.82 | +811.9% |
| XFOR X4 Pharmaceuticals, Inc | 27.8M | 0.5% | 6.7M | 4.04 | +44.3% |
| GH Guardant Health, Inc. | 27.7M | 0.5% | 300.0K | 170.69 | +191.8% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 27.5M | 0.5% | 377.5K | 77.42 | +80.0% |
| IVVD Invivyd, Inc. | 27.1M | 0.5% | 20.9M | 1.00 | +57.2% |
| SION Sionna Therapeutics, Inc. | 26.4M | 0.5% | 658.4K | 5.29 | -76.8% |
| AXSM Axsome Therapeutics, Inc. | 25.3M | 0.5% | 149.9K | 207.77 | +77.6% |
| RVMD Revolution Medicines, Inc. | 25.1M | 0.5% | 258.6K | 209.46 | +479.3% |
| SABS SAB Biotherapeutics, Inc. | 24.6M | 0.5% | 6.4M | 3.78 | +88.1% |
| BLTE BELITE BIO, INC | 24.2M | 0.5% | 152.0K | 161.06 | +154.0% |
| TENX TENAX THERAPEUTICS, INC. | 23.2M | 0.5% | 1.4M | 1.75 | -70.7% |
| AXGN Axogen, Inc. | 23.1M | 0.5% | 697.3K | 50.40 | +223.9% |
| VRDN Viridian Therapeutics, Inc.\DE | 22.9M | 0.4% | 1.2M | 24.29 | +33.9% |
| OBIO Orchestra BioMed Holdings, Inc. | 21.4M | 0.4% | 5.0M | 5.36 | +120.6% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →